20.2 Systemic Immunosuppressive & Biologic Therapies

20.2 Systemic Immunosuppressive & Biologic Therapies

Conventional Systemic Immunosuppressants in Dermatovenereology

Conventional disease-modifying antirheumatic drugs (cDMARDs) remain primary systemic options across European healthcare systems due to oral bioavailability, established efficacy, and low acquisition cost.

1. Methotrexate (MTX)

• Molecular Mechanism: Methotrexate is a structural analogue of folic acid. While high oncologic doses act via competitive inhibition of dihydrofolate reductase (DHFR) to halt de novo thymidylate and purine synthesis, its low-dose anti-inflammatory actions in dermatology (10–25 mg/week) operate primarily through competitive inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase and thymidylate synthase. AICAR accumulation leads to intracellular accumulation of AMP and extracellular release of adenosine. Extracellular adenosine binds to A2A adenosine receptors on lymphocytes and macrophages, potently suppressing pro-inflammatory cytokine release (TNF-α, IL-12, IFN-γ) and inducing activated T-cell apoptosis.
• Dosing Schedule & Critical Warning: MTX is administered strictly ONCE WEEKLY (10 to 25 mg/week), taken orally or via subcutaneous injection. Subcutaneous administration offers higher bioavailability (>90%) with fewer gastrointestinal adverse effects.
  • Fatal Prescribing Pitfall: Accidental daily administration of MTX is a catastrophic medical emergency causing profound bone marrow aplasia, severe agranulocytic sepsis, and diffuse gastrointestinal/cutaneous necrotizing ulcerations.
• Mandatory Folic Acid Supplementation: Folic acid (5 mg once or twice weekly, taken 24 to 48 hours after the MTX dose, or 1 mg daily except on the MTX administration day) is mandatory. This protects against mucosal ulceration, nausea, transaminitis, and megaloblastic cytopenias without blunting therapeutic efficacy.
• Emergency Rescue with Folinic Acid (Leucovorin): In cases of acute overdose or sudden pancytopenia, calcium folinate (leucovorin) must be administered immediately. Leucovorin bypasses DHFR by directly providing 5-formyl-tetrahydrofolate. Regular folic acid is completely ineffective in acute toxicity because DHFR is competitively blocked.
• Pre-Treatment Screening: Complete blood count (CBC) with differential, liver transaminases (ALT, AST, ALP, total bilirubin, albumin), renal function (serum creatinine, eGFR; MTX is 80%–90% eliminated unchanged renally; strictly contraindicated if eGFR <30 mL/min), viral hepatitis serology (HBsAg, anti-HBc, anti-HBs, anti-HCV), HIV serology, chest radiography, and pregnancy testing.
• Teratogenicity & Contraception: Potent teratogen and abortifacient (causes fetal aminopterin syndrome: cranial dysostosis, facial dysmorphism, cardiac defects). Women of childbearing potential need effective contraception during treatment and for at least 6 months afterwards (EU product information). Advice for men varies between product labels and doses; check the current SmPC.
• Monitoring Cumulative Hepatotoxicity: Serial liver biopsies have been largely replaced in European guidelines by non-invasive biomarkers:
  1. Serum Procollagen III N-terminal Peptide (PIIINP): Measured every 3 months. Persistent elevations (>4.2 µg/L in at least 3 samples over a 12-month period) indicate active hepatic fibrogenesis, warranting dosage reduction, hepatology referral, or transient elastography.
  2. Transient Elastography (FibroScan): Measures liver stiffness. Values <7.0 to 7.5 kPa reliably exclude advanced fibrosis; values >7.5 to 9.5 kPa indicate suspected fibrosis requiring specialist evaluation.
• Acute Idiosyncratic Hypersensitivity Pneumonitis: Characterized by acute dry cough, dyspnoea, fever, and bilateral interstitial/alveolar infiltrates on imaging. It is non-dose-dependent and requires immediate MTX cessation and high-dose systemic corticosteroid therapy.

2. Ciclosporin A (Cyclosporine)

• Molecular Mechanism: A neutral cyclic peptide of 11 amino acids. It binds to the intracellular immunophilin cyclophilin A. The resulting drug-cyclophilin complex binds with high affinity to and inhibits calcineurin, a calcium- and calmodulin-activated protein phosphatase. This blocks the dephosphorylation of NFATc, halting its nuclear translocation and silencing transcription of IL-2 (the primary autocrine growth factor driving T-cell clonal expansion) as well as IL-3, IL-4, TNF-α, and IFN-γ.
• Clinical Dosing & Rescue Utility: Dosed at 2.5 to 5.0 mg/kg/day in two divided doses 12 hours apart. Characterized by rapid clinical onset (within 1 to 2 weeks), making it the premier short-term "crisis buster" for acute erythrodermic psoriasis, severe atopic flares, and acute pyoderma gangrenosum.
• Duration Threshold: Restricted to short-term therapy (typically ≤12 to 16 weeks, maximum 1 to 2 years continuous) to avoid irreversible renal structural damage.
• Nephrotoxicity & The 25–30% Creatinine Rule: Ciclosporin induces acute dose-dependent vasoconstriction of afferent glomerular arterioles (functional nephrotoxicity). Prolonged use leads to structural nephrotoxicity characterized by striped interstitial fibrosis and tubular atrophy.
  • Monitoring Rule: Blood pressure and serum creatinine must be checked every 2 weeks for the first 3 months, then monthly. If serum creatinine rises more than 25% above the patient's pre-treatment baseline (the EU product information threshold; some guidelines use 30%) on repeated measurement, the dose must be reduced by 25% to 50%. If creatinine does not return to within that range, ciclosporin must be discontinued.
• Hypertension Management: Up to 30%–50% of patients develop arterial hypertension. The first-line antihypertensive agents are dihydropyridine calcium channel blockers (e.g., amlodipine, nifedipine), which counteract afferent arteriolar vasoconstriction.
  • Pharmacokinetic Trap: Non-dihydropyridine CCBs (diltiazem, verapamil) are strictly contraindicated because they potently inhibit CYP3A4, precipitating massive toxic surges in serum ciclosporin levels.
• Electrolytes & Cutaneous Toxicities: Induces hypomagnesaemia (renal magnesium wasting), hyperkalaemia, gingival hyperplasia (accentuated by poor oral hygiene and calcium channel blockers), hypertrichosis, and tremors.
• Photocarcinogenesis Interaction: Markedly elevates the risk of non-melanoma skin cancer (cutaneous squamous cell carcinoma) and lymphoma, especially in patients with prior extensive PUVA phototherapy (>200 sessions). Concurrent phototherapy with ciclosporin is strictly contraindicated.

3. Azathioprine (AZA)

• Molecular Mechanism: A prodrug that undergoes non-enzymatic cleavage by glutathione to 6-mercaptopurine (6-MP). 6-MP is subsequently metabolized through three competing enzymatic pathways:
  1. Thiopurine S-methyltransferase (TPMT): Inactivates 6-MP to 6-methylmercaptopurine (6-MMP) (excess 6-MMP drives hepatotoxicity).
  2. Xanthine oxidase (XO): Oxidizes 6-MP to inactive 6-thiouric acid.
  3. Hypoxanthine-guanine phosphoribosyltransferase (HGPRT): Converts 6-MP into 6-thioguanine nucleotides (6-TGN). Active 6-TGN metabolites incorporate into leukocyte DNA and RNA, inducing chromosome breaks, blocking de novo purine synthesis, inhibiting Rac1, and triggering T-lymphocyte apoptosis.
• NUDT15 Gene: Encodes nudix hydrolase 15, which cleanses toxic 6-thio-dGTP. Loss-of-function variants in NUDT15 precipitate severe early myelosuppression and acute alopecia (predominantly in Asian and Hispanic populations).
• Mandatory Pharmacogenomic Screening: Testing for TPMT and NUDT15 (genotyping or TPMT red blood cell enzymatic phenotyping) is mandatory before prescribing azathioprine:
  • Normal / High TPMT Activity: Standard dosing of 2.0 to 2.5 mg/kg/day.
  • Intermediate TPMT Activity (Heterozygous, ~10% of European population): Reduce starting dose by 50% (1.0 to 1.5 mg/kg/day) with frequent hematological monitoring.
  • Low or Deficient TPMT Activity (Homozygous Null, ~1 in 300 individuals): ABSOLUTE CONTRAINDICATION! Standard doses cause fatal bone marrow aplasia and profound agranulocytosis.
• Lethal Drug Interaction with Xanthine Oxidase Inhibitors: Co-administration of azathioprine with allopurinol or febuxostat completely blocks xanthine oxidase. This shunts the entirety of 6-MP into the HGPRT pathway, driving astronomical levels of cytotoxic 6-TGN and triggering fatal bone marrow suppression. If combination cannot be avoided, the azathioprine dose must be drastically slashed to 25% of standard dose (a 75% reduction) with intense CBC surveillance.

4. Mycophenolate Mofetil (MMF) & Enteric-Coated Mycophenolic Acid (EC-MPS)

• Molecular Mechanism: MMF is the 2-morpholinoethyl ester prodrug of mycophenolic acid (MPA). MPA is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), specifically the type II isoform expressed predominantly in activated lymphocytes. IMPDH is the rate-limiting enzyme in the de novo synthesis of guanine nucleotides. While other human cells can salvage purines via the hypoxanthine-guanine phosphoribosyltransferase pathway, T and B lymphocytes lack significant salvage pathways and depend exclusively on de novo synthesis. IMPDH inhibition depletes intracellular dGTP, selectively suppressing lymphocyte proliferation, antibody production, and cell adhesion.
• Clinical Indications: Autoimmune bullous diseases (pemphigus vulgaris, bullous pemphigoid), pyoderma gangrenosum, cutaneous lupus erythematosus, and dermatomyositis.
• Adverse Effects: Dose-limiting gastrointestinal distress (nausea, diarrhea, abdominal cramps; enteric-coated EC-MPS improves upper GI tolerability), myelosuppression (neutropenia), and opportunistic viral infections (HSV, VZV, CMV).
• Severe Teratogenicity (Mycophenolate Embryopathy): Causes spontaneous first-trimester pregnancy loss (>40%) and severe structural malformations: microtia/anotia with external auditory canal atresia, cleft lip and palate, micrognathia, ocular coloboma, and congenital heart defects. Strict dual contraception is required 1 month before, during, and for at least 6 weeks post-discontinuation in women (and 90 days in men).

---

Standardized European Pre-Biologic Screening Protocol

Prior to the initiation of any biologic or targeted synthetic DMARD in dermatovenereology, European consensus guidelines mandate a structured baseline screening protocol to mitigate infection, malignancy, and organ toxicity.

Pre-Biologic Screening Checklist Table

---

Targeted Biologic Therapies: Molecular Classes & Landmark Pearls

Biologics have revolutionized the management of moderate-to-severe plaque psoriasis and atopic dermatitis by selectively interrupting pathogenic cytokine cascades.

Comparative Biologic Mechanism & Clinical Profile Table

Critical Clinical Class Pearls

• Certolizumab Pegol in Pregnancy: Consists of a humanized Fab' antigen-binding fragment conjugated to polyethylene glycol (PEG), completely lacking an Fc crystallizable region. Because transplacental transfer during the second and third trimesters relies strictly on active transport via the neonatal Fc receptor (FcRn), certolizumab pegol does not cross the placenta and does not pass into breast milk in clinically meaningful quantities. It is the biologic of choice for women of childbearing potential, during pregnancy, and throughout lactation.
• IL-17 Blockade and Mucocutaneous Candidiasis: IL-17A and IL-17F are essential for mucosal epithelial defence against Candida albicans (inducing antimicrobial peptides, defensins, and neutrophil recruitment). Up to 10%–15% of patients treated with IL-17 inhibitors (especially dual IL-17A/F blockade with bimekizumab) develop mild-to-moderate oral or vulvovaginal candidiasis, easily managed with topical antifungals or oral fluconazole without drug discontinuation.
• IL-17 Blockade and Inflammatory Bowel Disease (IBD): IL-17 maintains tight junctions and mucosal integrity in the gut epithelium. Neutralization of IL-17 can trigger new-onset Crohn disease or ulcerative colitis, or provoke catastrophic flares of quiescent IBD. IL-17 inhibitors are contraindicated in patients with active or severe IBD.

---

Small-Molecule Targeted Synthetic DMARDs (tsDMARDs)

Targeted small molecules provide oral therapeutic alternatives to injectable biologics, acting downstream inside immune cells.

1. Phosphodiesterase-4 (PDE4) Inhibitor: Apremilast

• Molecular Mechanism: Oral small molecule that selectively inhibits phosphodiesterase-4 (PDE4), preventing the degradation of intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP levels activate protein kinase A (PKA), which downregulates NF-κB-driven pro-inflammatory cytokines (TNF-α, IL-23, IL-17) while upregulating the potent anti-inflammatory cytokine IL-10.
• Clinical Indications: Moderate plaque psoriasis, psoriatic arthritis, and oral aphthae of Behçet disease.
• The Key Advantage: Requires ZERO mandatory routine laboratory blood monitoring! It does not cause bone marrow suppression, hepatotoxicity, nephrotoxicity, or latent TB reactivation.
• Adverse Effects: Nausea and diarrhea occur in up to 15%–20% of patients during the initial 2 to 4 weeks of therapy (mitigated by a 5-day dose-titration pack to 30 mg twice daily). Causes mild weight loss (monitor body weight) and carries a regulatory warning regarding new-onset depression or suicidal ideation.

2. Oral Janus Kinase (JAK) Inhibitors

• Agents & Targets: Tofacitinib (JAK1/JAK3), Baricitinib (JAK1/JAK2), Upadacitinib (selective JAK1), and Abrocitinib (selective JAK1).
• Mechanism: Reversibly bind to the adenosine triphosphate (ATP)-binding pocket of the JAK catalytic domain, preventing transphosphorylation and recruitment of signal transducers and activators of transcription (STAT). By interrupting the intracellular JAK-STAT pathway, they block the signaling cascades of multiple key inflammatory cytokines simultaneously (IL-4, IL-13, IL-31 [the principal neuroimmune pruritus cytokine], IL-22, IFN-α, and IFN-γ). In atopic dermatitis, oral JAK1 inhibitors deliver near-instantaneous pruritus relief (often within 24 to 48 hours).
• European Medicines Agency (EMA) Class-Wide Safety Warnings: Following the post-marketing ORAL Surveillance study, the EMA Pharmacovigilance Risk Assessment Committee (PRAC) issued strict class-wide safety restrictions for all systemic JAK inhibitors:
  1. Major Adverse Cardiovascular Events (MACE): Elevated incidence of myocardial infarction and ischemic stroke.
  2. Venous Thromboembolism (VTE): Deep vein thrombosis (DVT) and pulmonary embolism (PE).
  3. Malignancies: Non-melanoma skin cancer (NMSC), lymphoma, and lung cancer.
  4. Serious Infections & Herpes Zoster: High rates of varicella-zoster virus reactivation (recombinant zoster vaccination [Shingrix] is strongly recommended prior to therapy).
  5. All-Cause Mortality: Increased in older cohorts.
• EMA Prescribing Mandate: In patients aged ≥65 years, patients with history of smoking or current smokers, patients with established cardiovascular disease, or patients with risk factors for malignancy or VTE, JAK inhibitors should be used only if no suitable treatment alternatives are available, and administered at the lowest effective dose.
• Required Laboratory Monitoring: CBC (anemia, neutropenia, lymphopenia), fasting lipid profile (dose-dependent increases in total cholesterol, LDL, and HDL at 4–12 weeks), liver enzymes, renal function, and creatine phosphokinase (CPK).